David Strasser
Cardiovascular Disease · Erie, PANPI 1285638114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 83.7% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $245, more than ten times the $18 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.
Across 27 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$405
- Stryker$27
- Amarin Pharma, Inc.$20
- Amgen$16
- E.r. Squibb & Sons, L.L.C.$15
Across 4 payments — averaging $5255.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21K
What the payments were for
- Food & beverage$484100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $405 |
| Stryker | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$484 in reported general payments places this provider in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $148,260 |
| Repatha SureclickEvolocumab | 75 | $64,788 |
| XareltoRivaroxaban | 47 | $49,084 |
| EntrestoSacubitril/Valsartan | 13 | $24,717 |
| JardianceEmpagliflozin | 25 | $22,816 |
| Praluent PenAlirocumab | 17 | $12,100 |
| Ezetimibe | 342 | $7,290 |
| Metoprolol Succinate | 502 | $6,905 |
| Atorvastatin Calcium | 351 | $4,431 |
| Rosuvastatin Calcium | 298 | $3,131 |
| Ranolazine ErRanolazine | 60 | $3,057 |
| ClopidogrelClopidogrel Bisulfate | 199 | $2,507 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 187 | $2,300 |
| Prasugrel Hcl | 34 | $2,155 |
| Potassium Chloride | 111 | $1,819 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Erie
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
- Rajesh DaveCamp Hill$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.